BlackRock Discloses 5.0% Passive Stake in Altimmune, Inc.
Ticker: ALT · Form: SC 13G · Filed: Jan 26, 2024 · CIK: 1326190
| Field | Detail |
|---|---|
| Company | Altimmune, Inc. (ALT) |
| Form Type | SC 13G |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a 5.0% passive stake in Altimmune, Inc. as of year-end 2023.**
AI Summary
BlackRock Inc., a major investment firm, reported owning 5.0% of Altimmune, Inc.'s common stock as of December 31, 2023. This filing, an SC 13G, indicates BlackRock holds these shares for investment purposes and not to influence company management. This matters to investors because it signals that a large, sophisticated institutional investor sees value in Altimmune, Inc. stock, potentially boosting confidence, but also means a significant block of shares is held by an entity that could sell without directly engaging with management.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant but passive stake in Altimmune, Inc., which can be seen as a vote of confidence in the company's long-term prospects.
Risk Assessment
Risk Level: low — The filing indicates a passive investment, meaning BlackRock is not seeking to influence management, which generally poses low risk to current operations.
Analyst Insight
Investors should note BlackRock's passive stake as a potential indicator of institutional confidence, but understand it doesn't imply active management involvement. Monitor future filings for any changes in BlackRock's ownership percentage or investment intent.
Key Numbers
- 5.0% — Ownership Percentage (BlackRock's stake in Altimmune, Inc. common stock as of December 31, 2023)
Key Players & Entities
- BlackRock Inc. (company) — the investment firm filing the SC 13G
- Altimmune, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- 5.0% (dollar_amount) — the percentage of Altimmune, Inc. common stock owned by BlackRock Inc.
Forward-Looking Statements
- BlackRock will maintain a passive investment stance in Altimmune, Inc. (BlackRock Inc.) — high confidence, target: Next 12 months
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) as indicated by the 'X' in the appropriate box.
Who is the 'Subject Company' in this filing?
The 'Subject Company' is Altimmune, Inc., with a Central Index Key (CIK) of 0001326190.
Who is the 'Filing By' entity in this document?
The 'Filing By' entity is BlackRock Inc., with a Central Index Key (CIK) of 0001364742.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
What is the CUSIP Number for the class of securities reported?
The CUSIP Number for the Common Stock of Altimmune, Inc. is 02155H200.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 26, 2024 regarding Altimmune, Inc. (ALT).